Ausdal Financial Partners Inc. lifted its holdings in shares of Allergan plc (NYSE:AGN) by 67.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,900 shares of the company’s stock after purchasing an additional 765 shares during the quarter. Ausdal Financial Partners Inc.’s holdings in Allergan were worth $311,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in AGN. Advisory Services Network LLC raised its position in Allergan by 148.9% in the 4th quarter. Advisory Services Network LLC now owns 6,462 shares of the company’s stock valued at $1,057,000 after buying an additional 3,866 shares during the last quarter. Toronto Dominion Bank raised its position in Allergan by 13.0% in the 4th quarter. Toronto Dominion Bank now owns 143,364 shares of the company’s stock valued at $23,452,000 after buying an additional 16,487 shares during the last quarter. AMS Capital Ltda acquired a new stake in Allergan in the 4th quarter valued at approximately $2,454,000. First Trust Advisors LP raised its position in Allergan by 58.8% in the 4th quarter. First Trust Advisors LP now owns 119,247 shares of the company’s stock valued at $19,506,000 after buying an additional 44,175 shares during the last quarter. Finally, Retirement Systems of Alabama raised its position in Allergan by 7.0% in the 4th quarter. Retirement Systems of Alabama now owns 290,274 shares of the company’s stock valued at $47,483,000 after buying an additional 19,082 shares during the last quarter. 79.76% of the stock is currently owned by institutional investors.
A number of equities research analysts recently issued reports on AGN shares. Cowen set a $280.00 target price on Allergan and gave the company a “buy” rating in a research report on Friday, October 20th. JPMorgan Chase & Co. set a $275.00 target price on Allergan and gave the company a “buy” rating in a research report on Sunday, October 22nd. Zacks Investment Research raised Allergan from a “sell” rating to a “hold” rating in a research report on Monday, October 23rd. Royal Bank of Canada set a $250.00 target price on Allergan and gave the company a “buy” rating in a research report on Sunday, October 29th. They noted that the move was a valuation call. Finally, Cantor Fitzgerald set a $231.00 target price on Allergan and gave the company a “hold” rating in a research report on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $227.23.
Allergan (NYSE:AGN) last issued its earnings results on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.74 by $0.12. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The company had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.28 billion. During the same period in the previous year, the company posted $3.90 EPS. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. research analysts anticipate that Allergan plc will post 15.57 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be paid a dividend of $0.72 per share. This is an increase from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a dividend yield of 1.76%. The ex-dividend date of this dividend is Tuesday, February 27th. Allergan’s payout ratio is currently -23.35%.
In other news, Director Christopher J. Coughlin purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 5th. The stock was acquired at an average cost of $163.30 per share, with a total value of $1,633,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider William Meury sold 58,879 shares of Allergan stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total value of $9,457,144.98. The disclosure for this sale can be found here. Insiders have bought a total of 17,630 shares of company stock valued at $2,890,057 over the last quarter. 0.36% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This article was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://stocknewstimes.com/2018/02/17/allergan-plc-agn-shares-bought-by-ausdal-financial-partners-inc.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.